Recursion Pharmaceuticals, Inc. RXRX Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s total cost of revenue?
- Recursion Pharmaceuticals, Inc. (RXRX) reported total cost of revenue of $12.49M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s total cost of revenue changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s total cost of revenue decreased by 42.8% year-over-year, from $21.83M to $12.49M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.